Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology.
about
Noninvasive imaging of cardiovascular injury related to the treatment of cancerA strategy for integrating essential three-dimensional microphysiological systems of human organs for realistic anticancer drug screening.The utility of serum biomarkers to detect myocardial alterations induced by Imatinib in rats.Risk of thrombosis in women with malignancies undergoing ovarian stimulation for fertility preservation.Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS)tcTKB: an integrated cardiovascular toxicity knowledge base for targeted cancer drugs.The cardiotoxicity of cetuximab as single therapy in Chinese chemotherapy-refractory metastatic colorectal cancer patients.Chemotherapy-related cardiotoxicity.The many lives of CTIP2: from AIDS to cancer and cardiac hypertrophy.Adverse reactions to oncologic drugs: spontaneous reporting and signal detection.Renal dysfunction and increased risk of cardiotoxicity with trastuzumab therapy: a new challenge in cardio-oncology.The Role of Biomarkers in Detection of Cardio-toxicity.Induced pluripotent stem-cell-derived cardiomyocytes: cardiac applications, opportunities, and challenges.Targeted Cancer Therapies and QT Interval Prolongation: Unveiling the Mechanisms Underlying Arrhythmic Complications and the Need for Risk Stratification Strategies.Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab.Mechanistic Systems Modeling to Improve Understanding and Prediction of Cardiotoxicity Caused by Targeted Cancer Therapeutics.Drug discovery models and toxicity testing using embryonic and induced pluripotent stem-cell-derived cardiac and neuronal cellsRole of renal function on the development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer.Neuroprotective activities of curcumin and quercetin with potential relevance to mitochondrial dysfunction induced by oxaliplatin.ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations.Assessment of the cardiac safety between cetuximab and panitumumab as single therapy in Chinese chemotherapy-refractory mCRC.Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors.Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule.Cardio-oncology: A Focus on Cardiotoxicity
P2860
Q27024715-7FD8D917-9963-44C6-ADD2-10BCD4A3E454Q34143251-1A6388F2-C252-49A6-8041-D37AAD48F845Q34292469-D1D74B5F-22A4-434B-87A9-881352FA6F33Q34428728-B84AC6E2-C3C5-4E6F-9063-AFA7F828C069Q35673776-E1B832FC-7DDA-4845-AC60-5202C16BA32AQ36613254-BA489F68-E468-49EB-91B3-D0A90EEAB256Q37613422-4A461527-0637-4BCA-9449-3459DFBE2D24Q38088974-EB372F72-7EE6-4995-B6BB-96AC820EA098Q38152295-D6D53797-636E-487F-8B7F-D307721CA57AQ38264389-8D763B5D-CBAA-41AC-8FDF-50ABE819ACB8Q38414100-A702DC22-1AA1-4775-AFC0-D1B113051151Q38728535-7E6F4B81-02AB-4F61-A18B-98A5EAA5F6F5Q38738472-09561FEE-5429-4293-AA6D-E6EBD8EA3C09Q38956949-AACF5331-BB02-4E04-B022-AF973E5BB98AQ39344380-E3D56EA8-4685-45E0-B478-684ADCFF71F0Q41688591-02730EC0-0644-405F-937C-0917AFC992D4Q42175982-B0A0B2D2-B2EE-490F-924B-AD1FDA84A606Q47600200-3DC48059-3266-49AC-8652-953C1388659DQ48155275-29D0D86A-803A-4CF6-A378-20D2BA9D42C9Q48299993-E982BAE7-4B12-4214-B7F9-19147A0C735BQ49164511-35834523-993E-4221-828E-F9263274A078Q49315568-2F9CDB87-B0DE-49E8-BDD3-F03D65F2028CQ51066600-756B77A9-B718-4585-AE72-044F30716B26Q54263942-A98E67B2-8301-4AC9-B7B5-C049CF4F32C9Q57495835-E91BEDF0-4D8B-49FF-B1BE-7BD74FA68CC8
P2860
Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Cardiovascular toxicity of ant ...... in the era of cardio-oncology.
@en
Cardiovascular toxicity of ant ...... in the era of cardio-oncology.
@nl
type
label
Cardiovascular toxicity of ant ...... in the era of cardio-oncology.
@en
Cardiovascular toxicity of ant ...... in the era of cardio-oncology.
@nl
prefLabel
Cardiovascular toxicity of ant ...... in the era of cardio-oncology.
@en
Cardiovascular toxicity of ant ...... in the era of cardio-oncology.
@nl
P2860
P1476
Cardiovascular toxicity of ant ...... in the era of cardio-oncology.
@en
P2860
P2888
P304
P356
10.1007/S11739-011-0744-Y
P577
2011-12-13T00:00:00Z